News &amp; Updates

Empiric azithromycin appears to have no substantial impact on shock duration, mechanical ventilation duration, intensive care unit (ICU) length of stay (LOS), hospital LOS, or in-hospital mortality in septic shock patients admitted to the ICU, according to a study.

Can azithromycin shorten shock resolution in ICU patients?

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

COVID-19 vaccine boosters effective against Omicron in people with substance use disorder

29 May 2023 by

COVID-19 vaccine boosters provide protection against Omicron infection and related hospitalization among people with substance use disorder, researchers from the University of Hong Kong have reported.

COVID-19 vaccine boosters effective against Omicron in people with substance use disorder

29 May 2023

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

For individuals with increased projected risk of probable dementia or amnestic mild cognitive impairment (MCI) who are prescribed antihypertensive treatment, intensive systolic blood pressure (SBP) lowering confers greater cognitive benefits than standard treatment, according to a secondary analysis of the SPRINT trial.

Cognitive protection greater with intensive vs standard SBP lowering for high-risk individuals

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

Treatment with clevidipine in patients undergoing cardiac surgery leads to better perioperative blood pressure (BP) control relative to nicardipine, with a slight rise in cost and no significant difference in safety outcomes, a study has found.

Clevidipine trumps nicardipine for BP control in patients undergoing cardiac surgery

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

Adding glucagon-like peptide-1 receptor agonists (GLP1RA) onto metformin, sulfonylurea, or insulin treatment alone or in combination appears to reduce the incidence of major adverse cardiac events (MACE) and heart failure (HF) hospitalization relative to treatment with dipeptidyl peptidase-4 inhibitors (DPP4i), suggests a study.

GLP1RA added to antidiabetic drugs prevents MACE, HF hospitalization

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

Use of amiodarone in older patients with atrial fibrillation (AF) who are being treated with apixaban or rivaroxaban results in a higher risk of bleeding-related hospitalizations compared with the use of flecainide or sotalol, reports a study.

Amiodarone plus apixaban/rivaroxaban ups bleeding-related hospitalizations in older AF patients

Serum ADMA levels linked to circadian BP variability in glaucoma

Serum levels of asymmetric dimethylarginine (ADMA) seem to play a major role in the disturbance of circadian blood pressure (BP) variability in patients with glaucoma, suggests a recent study.

Serum ADMA levels linked to circadian BP variability in glaucoma

27 May 2023

Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents

Neither titanium-nitride-oxide (TiNO)–coated stents nor third-generation everolimus-eluting stents (EES) are necessarily better than the other in the treatment of patients with acute coronary syndromes (ACS), with a study showing no significant difference in long-term outcomes following placement of TiNO-coated stents or EES.

Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents

27 May 2023

Maternal influenza vaccination reduces ILI risk in infants

27 May 2023 by

Administration of maternal influenza vaccine during the first- or second-trimester of pregnancy reduces the risk of influenza-like illness (ILI) in the offspring, according to a study presented at ESPID 2023.

Maternal influenza vaccination reduces ILI risk in infants